HALP Score as a New Prognostic Factor for Patients with Metastatic Bladder Cancer

Simple item page
dc.contributor.authorAcar O.
dc.contributor.authorAyhan M.
dc.contributor.authorDemir B.
dc.contributor.authorEkinci F.
dc.contributor.authorAytac A.
dc.contributor.authorErdogan A.P.
dc.date.accessioned2024-07-22T08:02:07Z
dc.date.available2024-07-22T08:02:07Z
dc.date.issued2023
dc.description.abstractObjective: To investigate the effect of the haemoglobin, albumin, lymphocyte, and platelet (HALP) score (Haemoglobin, Albumin, Lymphocyte, Platelet count) on survival as a new prognostic factor in metastatic bladder cancer. Study Design: Descriptive study. Place and Duration of the Study: Department of Medical Oncology, Celal Bayar University, Manisa, Turkey, and Adnan Menderes University, Aydin, Turkey, from 2010 to 2020. Methodology: The medical charts of patients with metastatic bladder cancer were reviewed retrospectively. Prognostic value of the HALP score as a marker of overall survival was examined through a receiver operating characteristic (ROC) curve analysis. Results: The cut-off value for the HALP score in the ROC curve analysis was 29. The median overall survival (OS) was 19 months when the HALP score was less than 29, and the median OS was 40 months when the HALP score was 29 or greater, and this finding was statistically significant (p = 0.003). Conclusion: The HALP score is closely related to prognosis in metastatic bladder cancer. A high HALP score is associated with better survival outcomes. © 2023 College of Physicians and Surgeons Pakistan. All rights reserved.
dc.identifier.DOI-ID10.29271/jcpsp.2023.12.1405
dc.identifier.issn1022386X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11732
dc.language.isoEnglish
dc.publisherCollege of Physicians and Surgeons Pakistan
dc.rightsAll Open Access; Gold Open Access
dc.subjectAlbumins
dc.subjectHemoglobins
dc.subjectHumans
dc.subjectLymphocytes
dc.subjectPrognosis
dc.subjectRetrospective Studies
dc.subjectUrinary Bladder Neoplasms
dc.subjectalbumin
dc.subjectalkaline phosphatase
dc.subjectbilirubin
dc.subjectC reactive protein
dc.subjectcreatinine
dc.subjecthemoglobin
dc.subjectalbumin
dc.subjecthemoglobin
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectbladder cancer
dc.subjectbladder metastasis
dc.subjectbody mass
dc.subjectcancer prognosis
dc.subjectcancer survival
dc.subjectclinical feature
dc.subjectclinical outcome
dc.subjectdistant metastasis
dc.subjectfemale
dc.subjectfollow up
dc.subjecthistopathology
dc.subjecthuman
dc.subjectlymphocyte
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectoverall survival
dc.subjectplatelet count
dc.subjectprogression free survival
dc.subjectreceiver operating characteristic
dc.subjectretrospective study
dc.subjecttransurethral resection of the bladder
dc.subjectTurkey (republic)
dc.subjectbladder tumor
dc.subjectpathology
dc.subjectprognosis
dc.titleHALP Score as a New Prognostic Factor for Patients with Metastatic Bladder Cancer
dc.typeArticle

Files

Collections

Scopus Koleksiyonu